These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 16962019)

  • 21. Immunosuppression and sebaceous tumors: a confirmed diagnosis of Muir-Torre syndrome unmasked by immunosuppressive therapy.
    Landis MN; Davis CL; Bellus GA; Wolverton SE
    J Am Acad Dermatol; 2011 Nov; 65(5):1054-1058.e1. PubMed ID: 21550136
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Muir-Torre syndrome.
    Lachiewicz AM; Wilkinson TM; Groben P; Ollila DW; Thomas NE
    Am J Clin Dermatol; 2007; 8(5):315-9. PubMed ID: 17902735
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Retroperitoneal undifferentiated pleomorphic sarcoma having microsatellite instability associated with Muir-Torre syndrome: case report and review of literature.
    Lee N; Luthra R; Lopez-Terrada D; Wang WL; Lazar AJ
    J Cutan Pathol; 2013 Aug; 40(8):730-3. PubMed ID: 23672746
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extraocular sebaceous carcinoma in a patient with Muir-Torre syndrome.
    Harrington CR; Egbert BM; Swetter SM
    Dermatol Surg; 2004 May; 30(5):817-9. PubMed ID: 15099333
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sebaceous Neoplasms.
    Flux K
    Surg Pathol Clin; 2017 Jun; 10(2):367-382. PubMed ID: 28477886
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Muir-Torre syndrome.
    Cohen PR; Kohn SR; Davis DA; Kurzrock R
    Dermatol Clin; 1995 Jan; 13(1):79-89. PubMed ID: 7712655
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Muir-Torre syndrome caused by partial duplication of MSH2 gene by Alu-mediated nonhomologous recombination.
    Yanaba K; Nakagawa H; Takeda Y; Koyama N; Sugano K
    Br J Dermatol; 2008 Jan; 158(1):150-6. PubMed ID: 17941949
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Multiple sebaceous tumors with colon cancer--Muir-Torre syndrome].
    Vajda A; Scharrer K; Baló-Banga JM
    Orv Hetil; 2003 May; 144(20):985-9. PubMed ID: 12830729
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patients with a new-onset cutaneous sebaceous neoplasm following immunosuppression should be evaluated for Muir-Torre syndrome with germline mismatch repair gene mutation analysis: case reports.
    Cohen PR; Kurzrock R
    Dermatol Online J; 2024 Mar; 30(1):. PubMed ID: 38762859
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Muir-Torre Syndrome: expanding the genotype and phenotype--a further family with a MSH6 mutation.
    Murphy HR; Armstrong R; Cairns D; Greenhalgh KL
    Fam Cancer; 2008; 7(3):255-7. PubMed ID: 18236172
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Muir-Torre syndrome and Turcot syndrome].
    Velter C; Caussade P; Fricker JP; Cribier B
    Ann Dermatol Venereol; 2017; 144(8-9):525-529. PubMed ID: 28256262
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Microsatellite instability and immunostaining for MSH-2 and MLH-1 in cutaneous and internal tumors from patients with the Muir-Torre syndrome.
    Machin P; Catasus L; Pons C; Muñoz J; Conde-Zurita JM; Balmaña J; Barnadas M; Martí RM; Prat J; Matias-Guiu X
    J Cutan Pathol; 2002 Aug; 29(7):415-20. PubMed ID: 12139636
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of immunohistochemistry in the Muir-Torre Syndrome.
    Oliveira CM; Campos JG; Maia MR; Lobo LE; Valle FF
    An Bras Dermatol; 2015; 90(3 Suppl 1):168-70. PubMed ID: 26312706
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Deceptively Innocent Façade of Sebaceous Carcinoma in Muir-Torre Syndrome.
    Cox SV; Smith J
    Dermatol Surg; 2021 Jun; 47(6):828-829. PubMed ID: 33038102
    [No Abstract]   [Full Text] [Related]  

  • 35. Sebaceous gland tumors of the eyelids and conjunctiva in the Muir-Torre syndrome: a clinicopathologic study of five cases and literature review.
    Rishi K; Font RL
    Ophthalmic Plast Reconstr Surg; 2004 Jan; 20(1):31-6. PubMed ID: 14752307
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Muir-Torre syndrome and recent updates on screening guidelines: The link between colorectal tumors and sebaceous adenomas in unusual locations.
    Shaker N; Shaker N; Abid A; Shah S; Shakra RA; Sangueza OP
    J Surg Oncol; 2023 Dec; 128(8):1380-1384. PubMed ID: 37706607
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Muir-Torre syndrome: role of the dermatopathologist in diagnosis.
    Curry ML; Eng W; Lund K; Paek D; Cockerell CJ
    Am J Dermatopathol; 2004 Jun; 26(3):217-21. PubMed ID: 15166510
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Muir-Torre syndrome.
    Ponti G; Ponz de Leon M
    Lancet Oncol; 2005 Dec; 6(12):980-7. PubMed ID: 16321766
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reticulated acanthoma with sebaceous differentiation: another sebaceous neoplasm associated with Muir-Torre syndrome?
    Shon W; Wolz MM; Newman CC; Bridges AG
    Australas J Dermatol; 2014 Nov; 55(4):e71-3. PubMed ID: 23651324
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identifying Muir-Torre syndrome in a patient with glioblastoma multiforme.
    Park DM; Yeaney GA; Hamilton RL; Mabold J; Urban N; Appleman L; Flickinger J; Lieberman F; Mintz A
    Neuro Oncol; 2009 Aug; 11(4):452-5. PubMed ID: 19028998
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.